Researchers created a new kind of cancer drug that can grab a mutant protein while also carrying a second hit against the ...

The gene p53 acts as a tumor suppressor and often is called the ‘guardian of the genome.’ This gene is central to maintaining genomic stability, which prevents mutations from accumulating and leading ...

No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2007 ASCO Annual Meeting. This abstract does not include a full text component.

Wistar Institute scientist Maureen Murphy wants to solve a decades-long mystery: Why is ovarian cancer often resistant to hormone therapy? In a recently published study, she shared a new theory as to ...

TP53 mutations are crucial in cancer development and treatment response, influenced by genetic and environmental factors. In CLL and AML, TP53 serves as a significant prognostic marker, affecting ...

Figure 8: Regulation of ALDH3A1 and NECTIN4 by p53. Researchers Jessica J. Miciak, Lucy Petrova, Rhythm Sajwan, Aditya Pandya, Mikayla Deckard, Andrew J. Munoz, and Fred Bunz from the Sidney Kimmel ...

Over 50% of human cancers are thought to carry a mutation of the p53 gene. P53 is a master at regulating the expression of genes, influencing cellular stress response, DNA damage repair, and apoptosis ...

A new prime editing sensor library targeting p53 mutations allowed scientists to interrogate thousands of tumor genotypes as they arose in endogenous contexts. Sánchez-Rivera and his team found that ...

Researchers found a way to screen cancer-linked gene mutations much more easily and quickly than existing approaches, using a variant of CRISPR genome-editing known as prime editing. Tumors can carry ...

A single sperm donor who carries a rare cancer-causing genetic mutation has fathered at least 197 children across 14 countries in Europe, according to a collaborative investigation by 14 European news ...